Insulin and Glucose Excursion Following Premeal Insulin Lispro or Repaglinide in Cystic Fibrosis–Related Diabetes
- 1 October 2001
- journal article
- research article
- Published by American Diabetes Association in Diabetes Care
- Vol. 24 (10) , 1706-1710
Abstract
OBJECTIVE—Insulin and glucose levels in response to premeal insulin lispro or repaglinide were evaluated in adult patients with cystic fibrosis–related diabetes (CFRD) without fasting hyperglycemia. RESEARCH DESIGN AND METHODS—Seven patients with CFRD were fed 1,000-kcal liquid mixed meals. Three study conditions were administered in random order on separate mornings: 1) no premeal diabetes medication, 2) insulin lispro, 0.1 unit/kg body wt premeal and 3) repaglinide 1 mg premeal. Glucose and insulin levels were measured every 20 min for 5 h. RESULTS—Fasting insulin and glucose levels were normal in patients with CFRD, but the peak glucose level was elevated. Insulin lispro significantly decreased the peak glucose level (P = 0.0004) and the 2-h (P = 0.001) and 5-h (P < 0.0001) glucose area under the curve (AUC). Repaglinide significantly decreased the 5-h glucose AUC (P = 0.03). Neither drug completely normalized cystic fibrosis glucose excursion at the doses used for this study. Insulin lispro significantly increased the 5-h insulin AUC (P = 0.04). CONCLUSIONS—In response to subcutaneous insulin lispro, postprandial glucose excursion was significantly diminished and insulin secretion was enhanced compared with a control meal in which no medication was given to patients with CFRD. The oral agent repaglinide resulted in lesser corrections in these parameters. Neither drug completely normalized glucose or insulin levels, suggesting that the doses chosen for this study were suboptimal. Placebo-controlled longitudinal studies comparing the effectiveness of repaglinide and insulin on glucose metabolic control as well as overall nutrition and body weight are needed to help determine optimal medical treatment of CFRD.Keywords
This publication has 21 references indexed in Scilit:
- Cystic fibrosis-related diabetes: an approach to diagnosis and managementPediatric Diabetes, 2000
- Effects of the Short-Acting Insulin Analog [Lys(B28),Pro(B29)] on Postprandial Blood Glucose Control in IDDMDiabetes Care, 1996
- Prandial Glycaemia After a Carbohydrate-rich Meal in Type I Diabetic Patients: Using the Rapid Acting Insulin Analogue [Lys(B28), Pro(B29)] Human InsulinDiabetic Medicine, 1996
- Diabetes mellitus in cystic fibrosis: effect of insulin therapy on lung function and infectionsActa Paediatrica, 1994
- [Lys(B28), Pro(B29)]-human insulin. A rapidly absorbed analogue of human insulinDiabetes, 1994
- Improvement of nutritional status and lung function after long-term nocturnal gastrostomy feedings in cystic fibrosisThe Journal of Pediatrics, 1994
- Effect of ATP-sensitive K+ channel regulators on cystic fibrosis transmembrane conductance regulator chloride currents.Journal of General Physiology, 1992
- Influence of the development of diabetes mellitus on clinical status in patients with cystic fibrosisEuropean Journal of Pediatrics, 1992
- Pancreatic endocrine function in cystic fibrosisThe Journal of Pediatrics, 1991
- Diabetes mellitus associated with cystic fibrosisThe Journal of Pediatrics, 1988